Sexual Health in Patients

It is estimated there are approximately 20 million new sexually transmitted infections (STIs) and 50,000 new HIV infections each year in the U.S. alone. Certain factors put patients at higher risk for STIs, and patients with STIs are 2 to 5 times more likely to contract HIV compared to uninfected peers. Those at high risk include:

• Patients with new or multiple sexual partners
• Sexually active patients under the age of 25
• Patients who practice unprotected sex

Sexual Health Profile

BioReference® offers Sexual Health Profiles for Males and Females that provide healthcare providers with comprehensive results for multiple infections from easy-to-collect samples, including blood and urine. The following disease markers and tests are included in the profiles:

Basic STI Urine Profile

BioReference® also offers a basic STI urine screen that is capable of rapidly identifying pathogens associated with common STIs. The STI Urine Profile includes testing for:

Test Benefits

The BioReference® Sexual Health and STI Urine Profiles have a range of benefits, including:

• Use of nucleic acid amplification tests (NAAT) offers high sensitivity and high specificity compared to pathogen identification by culture and wet-mount microscopy.
• Definitive identification of multiple pathogens leads to targeted treatment and reduced complications, as well as preventing disease progression and transmission.
• Use of non-invasive testing makes patients more comfortable than with use of traditional urethral swabs, leading to increased screening acceptance.
• Treatment management tools (such as previous test results and highlighted abnormalities on the test report) promote patient engagement and treatment compliance.

Patient Considerations

Any male patient experiencing urethral discharge, urethritis, epididymitis, orchitis, dysuria, prostatitis, reactive arthritis, genital inflammation, or pyelonephritis should be considered for testing. Any female experiencing abnormal vaginal discharge, dysuria, urethral discharge, chronic pelvic pain, genital inflammation, cervicitis, reactive arthritis, ectopic pregnancy, or preterm birth should be considered for testing. Testing can also be considered for asymptomatic patients at high risk for STI acquisition.